TickerFacts.

PDS Biotechnology Corp (PDSB): Shareholders' Equity

Annual figures by period end, from SEC filings.

$9.25M
As of 2025-12-31
-$3.58M
As of 2026-06-30
-40.5%
3-year compound annual growth
-19.4%
5-year compound annual growth
-22.8%
10-year compound annual growth
$122.48M2013-12-31: -$15.35M2014-12-31: -$27.83M2015-12-31: $122.48M2016-12-31: $89.28M2017-12-31: $62.37M2018-12-31: -$2.07M2019-12-31: $11.70M2020-12-31: $27.13M2021-03-31: $24.37M2021-06-30: $72.99M2021-09-30: $67.86M2021-12-31: $63.21M2022-03-31: $55.87M2022-06-30: $51.43M2022-09-30: $47.06M2022-12-31: $44.00M2023-03-31: $41.01M2023-06-30: $32.44M2023-09-30: $24.48M2023-12-31: $26.13M2024-03-31: $37.18M2024-06-30: $30.92M2024-09-30: $22.00M2024-12-31: $19.00M2025-03-31: $22.36M2025-06-30: $15.96M2025-09-30: $9.45M2025-12-31: $9.25M$9.25M
2013-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$9.25Mn/a2026-03-30, Balance as of period end
2025-09-30$9.45Mn/a2026-03-30, Balance as of period end
2025-06-30$15.96Mn/a2026-03-30, Balance as of period end
2025-03-31$22.36Mn/a2026-03-30, Balance as of period end
2024-12-31$19.00Mn/a2026-03-30, Balance as of period end
2024-09-30$22.00Mn/a2026-03-30, Balance as of period end
2024-06-30$30.92Mn/a2026-03-30, Balance as of period end
2024-03-31$37.18Mn/a2026-03-30, Balance as of period end
2023-12-31$26.13Mn/a2025-03-27, Balance as of period end
2023-09-30$24.48Mn/a2025-03-27, Balance as of period end
2023-06-30$32.44Mn/a2025-03-27, Balance as of period end
2023-03-31$41.01Mn/a2025-03-27, Balance as of period end
2022-12-31$44.00Mn/a2024-03-28, Balance as of period end
2022-09-30$47.06Mn/a2024-03-28, Balance as of period end
2022-06-30$51.43Mn/a2024-03-28, Balance as of period end
2022-03-31$55.87Mn/a2024-03-28, Balance as of period end
2021-12-31$63.21Mn/a2023-03-28, Balance as of period end
2021-09-30$67.86Mn/a2023-03-28, Balance as of period end
2021-06-30$72.99Mn/a2023-03-28, Balance as of period end
2021-03-31$24.37Mn/a2023-03-28, Balance as of period end
2020-12-31$27.13M+131.9%2022-03-31, Balance as of period end
2019-12-31$11.70Mn/m2021-03-18, Balance as of period end
2018-12-31-$2.07Mn/m2020-03-27, Balance as of period end
2017-12-31$62.37M-30.1%2019-02-21, Balance as of period end
2016-12-31$89.28M-27.1%2018-03-01, Balance as of period end
2015-12-31$122.48Mn/m2018-03-01, Balance as of period end
2014-12-31-$27.83Mn/m2017-03-02, Balance as of period end
2013-12-31-$15.35Mn/a2016-03-08, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
PDS Biotechnology Corp (PDSB)2025-12-31$9.25Mn/a
Yarrow Bioscience, Inc. (YARW)2025-12-31$27.77M-46.7%
Sunshine Biopharma Inc. (SBFM)2025-12-31$23.04M-2.0%
China Pharma Holdings, Inc. (CPHI)2025-12-31$22.74M+193.5%
Sol-Gel Technologies Ltd. (SLGL)2025-12-31$22.81M-20.9%
Veru Inc. (VERU)2025-09-30$18.33M-43.3%
Talphera, Inc. (TLPH)2025-12-31$17.04M+112.9%
Valion Bio, Inc. (VBIO)2025-12-31$16.80M+562.6%
Nuvectis Pharma, Inc. (NVCT)2025-12-31$18.41M+89.6%

Compare PDSB, YARW, SBFM, CPHI side by side · Screen every company in Pharmaceutical Preparations ↗